Literature DB >> 16618606

Late-onset and rare far-advanced pulmonary involvement in patients with sarcoidosis in Taiwan.

Chia-Wei Hsieh1, Der-Yuan Chen, Joung-Liang Lan.   

Abstract

BACKGROUND: Sarcoidosis is still considered a rare multisystem disorder in Taiwan, and data on the disease course and outcome are limited. We analyzed the clinical manifestations, disease course and complications in Taiwanese patients with sarcoidosis.
METHODS: A retrospective cohort design was used. Fifty-six patients with sarcoidosis diagnosed between 1985 and 2004 were included. Their clinical features, laboratory findings at initial presentation, disease course, and complications were analyzed.
RESULTS: Forty-three patients (76.8%) were female. The mean age at symptom onset was 47 years. The most common clinical symptoms were pulmonary (82.1%), cutaneous (23.2%), ophthalmic (19.6%), and articular (17.8%). Only two patients presented with Löfgren's syndrome. There was a seasonal variation in disease onset, with higher incidence in winter and early spring. No advanced pulmonary involvement was noted. Elevated levels of serum angiotensin converting enzyme (sACE) were found in 72.5% (29/40) of patients with active sarcoidosis, and significantly higher levels of sACE were found in patients with lung involvement (27.98+/-1.71 IU/L vs. 18.2+/-2.76 IU/L; p<0.01). In 50% (20/40) of patients, sACE levels declined significantly in parallel with clinical remission (24.75+/-1.53 IU/L vs. 16.33+/-1.21 IU/L; p<0.05). Spontaneous complete remission was found in 20.7% of patients, whereas 39.6% of patients with multiple extrapulmonary involvement responded poorly to intensive corticosteroids plus various immunosuppressants.
CONCLUSION: In this series, the mean age of disease onset was in middle age (mean, 47 years old), there was a low incidence of Löfgren's syndrome (3.6%), and no patients had advanced pulmonary syndrome. The results of this study also suggest that sACE might be a marker of pulmonary involvement that is also useful in monitoring disease activity.

Entities:  

Mesh:

Year:  2006        PMID: 16618606     DOI: 10.1016/S0929-6646(09)60117-0

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  3 in total

1.  Spinal cord sarcoidosis in Japan: utility of cerebrospinal fluid examination and nerve conduction study for diagnosis and prognosis prediction.

Authors:  Miwako Fujisawa; Michiaki Koga; Ryota Sato; Mariko Oishi; Yukio Takeshita; Takashi Kanda
Journal:  J Neurol       Date:  2022-04-17       Impact factor: 6.682

2.  Neurosarcoidosis: clinical characteristics, diagnosis, and treatment in eight Chinese patients.

Authors:  Fen Wang; Dongmei Guo; Zheng Liu; Aihong Zhou; Cuibai Wei; Jianping Jia
Journal:  Neurol Sci       Date:  2018-08-07       Impact factor: 3.307

3.  Internet search results correlate with seasonal variation of sarcoidosis.

Authors:  Amanda Stanton; Steven J Katz
Journal:  BMC Pulm Med       Date:  2021-07-13       Impact factor: 3.317

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.